Local administration of tranexamic acid during prostatectomy surgery: Effects on reducing the amount of bleeding

Nephro-Urology Monthly

Volumn 8, Issue 6, 2016, Pages

  Pourfakhr, Pejman ^a   Gatavi, Elham ^a   Gooran, Shahram ^a   Etezadi, Farhad ^a   Khajavi, Mohamad Reza ^a   Pourroustaei, Reza ^b   Moharari, Reza Shariat ^a   Najafi, Atabak ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bleeding; Prostatectomy; Tranexamic acid

Indexed keywords

HEMOGLOBIN; SODIUM CHLORIDE; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; HEMATOCRIT; HOSPITALIZATION; HUMAN; HUMAN CELL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

EID: 84994850719     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.40409     Document Type: Article

References (39)

1. Meigs JB, Mohr B, Barry MJ. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2011;54:935-44.
2. Kumsar Ş., Dirim A., Toksöz S., Sağlam H. S., Adsan Ö. Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR-P). Central European J Urol. 2011.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide. IARC; 210.
4. Crescenti A. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy:double blind, randomised, placebo controlled trial. British Med J. 2011:343.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. doi: 10.3322/caac.20006.[PubMed: 19474385].
6. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294(10):1255-9. doi:10.1001/jama.294.10.1255. [PubMed: 16160134].
7. Hugosson J, Stranne J, Carlsson SV. Radical retropubic prostatectomy:a review of outcomes and side-effects. Acta Oncol. 2011;50 Suppl 1:92-7. doi: 10.3109/0284186X.2010.535848. [PubMed: 21604947].
8. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144-54. doi: 10.1093/jnci/djn255.[PubMed: 18695132].
9. Finkelstein J, Eckersberger E, Sadri H, Taneja SS, Lepor H, Djavan B. OpenVersus LaparoscopicVersus Robot-Assisted Laparoscopic Prostatectomy:The European and US Experience. Rev Urol. 2010;12(1):35-43. [PubMed: 20428292].
10. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract. 2001;9(6):295-306. [PubMed: 11879332].
11. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N. EAU guidelines on prostate cancer. Arnhem: European Association of Urology; 2010.
12. Rassweiler J, Seemann O, Schulze M, Teber D, Hatzinger M, Frede T. Laparoscopic versus open radical prostatectomy: a comparative study at a single institution. J Urol. 2003;169(5):1689-93. doi:10.1097/01.ju.0000062614.56629.41. [PubMed: 12686809].
13. Djavan B, Eckersberger E, Finkelstein J. Oncologic, functional, and cost analysis of open, laparoscopic, and robotic radical prostatectomy. Eur Urol. 2010:371-8.
14. Djavan B, Agalliu I, Laze J, Sadri H, Kazzazi A, Lepor H. Blood loss during radical prostatectomy: impact on clinical, oncological and functional outcomes and complication rates. BJU Int. 2012;110(1):69-75. doi: 10.1111/j.1464-410X.2011.10812.x.[PubMed: 22145995].
15. Ficarra V, Novara G, Artibani W, Cesatri A, Galfano A, Graefen M. Retropubic, laparoscopic, and robot-assisted radical prostatectomy:a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009;55:1037-63.
16. Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. Vox Sang. 2010;98(1):2-11. doi: 10.1111/j.1423-0410.2009.01223.x.[PubMed: 19682346].
17. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080-99. doi: 10.1111/j.1537-2995.2010.02851.x. [PubMed:20738828].
18. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, Mc-Cluskey SA, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44(10):1453-62. doi: 10.1111/j.1537-2995.2004.04144.x.[PubMed: 15383018].
19. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009;108(3):759-69. doi:10.1213/ane.0b013e3181930a6e. [PubMed: 19224780].
20. Whitaker BI, Green J, King MR, Leibeg LL, Mathew SM, Schlumpf KS. The 2007 national blood collection and utilization survey report. 2010.
21. Miller RA, May MW, Hendry WF. The prevention of secondary hemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol. 1980;52:26-8.
22. Rannikko A, Petas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology. 2004;64(5):955-8. doi: 10.1016/j.urology.2004.07.008. [PubMed:15533485].
23. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-32.
24. Society of Thoracic Surgeons Blood Conservation Guideline Task F, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91(3):944-82. doi:10.1016/j.athoracsur.2010.11.078. [PubMed: 21353044].
25. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009;123(5):687-96. doi:10.1016/j.thromres.2008.09.015. [PubMed: 19007970].
26. Molenaar IQ,Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation:a systematic review and meta-analysis. Am J Transplant. 2007;7(1):185-94. doi: 10.1111/j.1600-6143.2006.01591.x.[PubMed: 17227567].
27. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;3:001886.
28. Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol. 2009;26(9):722-9. doi: 10.1097/EJA.0b013e32832c5280. [PubMed:19448549].
29. Sarris I, Arafa A, Konaris L, Kadir RA. Topical use of tranexamic acid to control perioperative local bleeding in gynaecology patients with clotting disorders: two cases. Haemophilia. 2007;13(1):115-6. doi:10.1111/j.1365-2516.2006.01386.x. [PubMed: 17212738].
30. Waly NG. Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions. Egypt Dent J. 1995;41(1):961-8. [PubMed: 9497628].
31. Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L. Can local application of Tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg. 2009;4:25. doi: 10.1186/1749-8090-4-25. [PubMed: 19538741].
32. Krohn CD, Sorensen R, Lange JE, Riise R, Bjornsen S, Brosstad F. Tranexamic acid given into the wound reduces postoperative blood loss by half in major orthopaedic surgery. Eur J Surg Suppl. 2003(588):57-61. [PubMed: 15200045].
33. Abrishami A, Chung F,Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and metaanalysis. Can J Anaesth. 2009;56(3):202-12. doi: 10.1007/s12630-008-9038-x.[PubMed: 19247741].
34. De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebocontrolled study. J Thorac Cardiovasc Surg. 2000;119(3):575-80.
35. Roy SP, Tanki UF, Dutta A., Jain SK, Nagi ON. Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012;20(12):2494-50.
36. Seo JG, Moon YW, Park SH, Kim SM, Ko KR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012.
37. Yasim A, Asik R, Atahan E. [Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery]. Anadolu Kardiyol Derg. 2005;5(1):36-40. [PubMed: 15755701].
38. Baric D, Biocina B, Unic D, Sutlic Z, Rudez I, Vrca VB, et al. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg.2007;31(3):366-71. doi: 10.1016/j.ejcts.2006.12.003. [PubMed: 17218108].
39. Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-analysis. J Bone Joint Surg Am. 2008;90(11):2399-407. doi: 10.2106/JBJS.G.01179.[PubMed: 18978408].